Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Galli, Luca
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	2	256	Europe, Canada, US, RoW	Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics	Locally Advanced or Metastatic Urothelial Carcinoma	01/25	01/25
RAPSON, NCT03230734 / 2016-004452-29: Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer	Active, not recruiting	2	70	Europe	Radium-223, Docetaxel	Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Bayer	Metastatic Castration-resistant Prostate Cancer	07/25	07/25
AxIn, NCT05817903: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients	Recruiting	2	118	Europe	Axitinib, Inlyta, Nivolumab	Consorzio Oncotech, Pfizer	Metastatic Renal Cell Carcinoma	04/26	04/27
NCT06235268: Prospective and Multicenter Italian Registry of Locally Advanced-Metastatic Urothelial Carcinoma	Recruiting	N/A	1000	Europe	Active systemic or non-systemic treatment (palliative or observation procedure)	Federation of Italian Cooperative Oncology Groups	Carcinoma, Urothelial	11/25	11/25